Insider Transactions in Q2 2021 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2021
|
Malcolm Salter Director |
SELL
Open market or private sale
|
Direct |
755
-4.84%
|
$27,935
$37.19 P/Share
|
|
Jun 14
2021
|
Alain J Cohen Director |
BUY
Other acquisition or disposition
|
Indirect |
22,598
+1.28%
|
-
|
|
Jun 14
2021
|
Alain J Cohen Director |
BUY
Other acquisition or disposition
|
Direct |
61,877
+49.89%
|
-
|
|
Jun 14
2021
|
Marc A Cohen Director |
BUY
Other acquisition or disposition
|
Indirect |
22,598
+1.19%
|
-
|
|
Jun 14
2021
|
Marc A Cohen Director |
BUY
Other acquisition or disposition
|
Direct |
92,817
+48.4%
|
-
|
|
May 21
2021
|
Malcolm Salter Director |
SELL
Open market or private sale
|
Direct |
755
-4.62%
|
$27,935
$37.12 P/Share
|
|
Apr 14
2021
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
711
+0.42%
|
$2,133
$3.55 P/Share
|
|
Apr 13
2021
|
Kenneth Carl Anderson Director |
BUY
Bona fide gift
|
Indirect |
2,278
+4.59%
|
-
|
|
Apr 13
2021
|
Kenneth Carl Anderson Director |
BUY
Bona fide gift
|
Direct |
2,278
+2.63%
|
-
|
|
Apr 05
2021
|
Marc A Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
553
+8.29%
|
$20,461
$37.51 P/Share
|
|
Apr 05
2021
|
Alain J Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
266
+50.0%
|
$9,842
$37.51 P/Share
|
|
Apr 05
2021
|
Malcolm Salter Director |
BUY
Grant, award, or other acquisition
|
Direct |
359
+2.15%
|
$13,283
$37.51 P/Share
|
|
Apr 05
2021
|
Adam Crystal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-63.74%
|
$555,000
$37.58 P/Share
|
|
Apr 05
2021
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.5 P/Share
|
|
Apr 05
2021
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
233
+0.28%
|
$8,621
$37.51 P/Share
|